Dr. Gerald (Gerry) Messerschmidt, MD, FACP is assuming the position of Chief Medical Officer. Gerry is a healthcare industry executive with extensive clinical development & regulatory affairs experience over 20 years. He is Board certified by the American Board of Medical Specialties in Internal Medicine, Medical Oncology and Hematology and trained and networked at the National Cancer Institute (Bethesda, MD) and past Head of the National Cancer Institute, Medicine branch, Experimental Hematology section. Gerry has extensive experience in development of small molecules, biologic products, medical devices, genetic modification of living organisms and immune modulation therapy as well as immunotherapy/cancer vaccine developments, including leading Ipilimumab studies performed by ICON. He has held previous positions, amongst others, as VP, Clinical Development at Talon Therapeutics (formerly Hana Biosciences) where he co-lead the successful development of Marqibo, a novel liposome plus vincristine product as well as Onyx Pharmaceuticals and ICON Clinical Research, and other executive roles within Ciba-Geigy (today Novartis).
Gerry received his MD degree from the University of Oregon and was also Director of the Bone Marrow Transplant Program at the University of Michigan.